Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort

Figures & data

Table 1 Baseline data from 334 patients in whom a differential blood cell blood count was available at visits V1–V3 as compared to 2,407 patients without differential blood cell count available at all time points V1–V3

	Current study population	Residual COSYCONET population	P-valuea
n	334	2,407	NA
Age, years	64.37±8.33	65.15±8.66	0.12
Male, %	63.2	58.5	0.1
BMI, kg/m^2	27.49±5.41	26.97±5.38	0.1
FEV1, % predicted	55.5±17.97	57.11±21.63	0.2
FEV1, l	1.66±0.64	1.67±0.73	0.77
No of exacerbations previous year	1.85±4.57	1.21±2.24	<0.001
6-MWD, min	429±98.42	418.95±109.83	0.09
BODE	2.1±1.88	2.27±2.01	0.16
SGRQ	43.09±19.69	42.63±20.03	0.69
ICS-containing treatment, %	57.8	63.9	0.03
History of asthma, %	20.1	18.4	0.45

Notes: Data are displayed as mean ± SD.

a t-test was calculated for continuous variables, Fisher’s exact test was calculated for dichotomous variables.

Abbreviations: NA, not applicable; BMI, body mass index; FEV₁, forced expiratory volume in 1 second; 6-MWD, 6-minute walking distance; BODE, score based on body mass index, obstruction, dyspnea, Exercise capacity; SGRQ, St George’s Respiratory Questionnaire; ICS, inhaled corticosteroid.

Figure 1 Absolute number and proportion of patients according to blood eos count at visits 1, 2, and 3.

Note: The proportions of participants at visit one are sequentially subdivided according to their eos blood count at visit 2, and the proportions of patients at visit 2 are sequentially subdivided according to their eos blood count at visit 3.
Abbreviation: eos, eosinophil.